New data from early studies of a novel compound IMO-8400 showed possible use as a treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs). The data were presented at the American Association of Immunologists (AAI) meeting being held in Boston, Massachusetts May 4-8, 2012. IMO-8400 is being developed by Idera Pharmaceuticals.
May 7, 2012